<DOC>
	<DOCNO>NCT03035708</DOCNO>
	<brief_summary>This study double-blind , randomize , placebo-controlled , parallel group , two-site study design assess effect varenicline compare placebo response vivo alcohol cue exposure human laboratory setting .</brief_summary>
	<brief_title>Human Laboratory Study Varenicline Alcohol Use Disorder</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , parallel group , two-site study design assess effect varenicline compare placebo response vivo alcohol cue exposure human laboratory setting . After sign informed consent , subject screen eligibility include medical history , physical examination , vital sign , electrocardiogram ( ECG ) , drink history timeline follow-back ( TLFB ) method , alcohol breathalyzer test , Clinical Institute Withdrawal Assessment Alcohol-revised ( CIWA ) , medication use , MINI neuropsychiatric interview , urine toxicology screen , clinical chemistry , response cue reactivity , Columbia Suicide Severity Rating Scale ( CSSR-S ) . Women child-bearting potential pregnancy test . If eligible study , subject randomize use stratify permuted block randomization procedure approximate 1:1 ratio ( target 24 subject per group - 12 subject per group per site ) receive either varenicline placebo 6 week . Any nicotine use versus use ( cigarette , cigar , chew tobacco , electronic cigarette , etc . ) week randomization stratification variable . Varenicline match placebo titrate first week study maintenance dose 1 mg ( active ) two capsule ( placebo ) take orally BID additional 5 week . Subjects see clinic screening , randomization 6 time study . A final follow-up telephone interview occur Week 9 ( 2 week end study visit ) . After first two week five week investigational product administration Study Week 3 Study Week 6 , respectively , subject undergo cue reactivity paradigm session ( HLAB ) include 4 individual visual analog scale ( VAS ) item assess alcohol craving , 2 VAS item assess emotional reactivity picture stimulus , 2 item assess emotional manipulation . Immediately HLAB session , subject view picture record emotion felt use Self-Manikin Assessment ( SAM ) . Other assessment baseline ( prior first dose investigational product ) and/or maintenance period include clinical chemistry , mood/behavior/thinking question , blood medication compliance , vital sign , ECG , concomitant medication , CIWA-AR , pregnancy test birth control method , drink goal , adverse event ( AEs ) , Alcohol Craving Questionnaire - Short Form ( ACQ-SF-R ) , Penn Alcohol Craving Scale ( PACS ) , Fagerstr√∂m Test Nicotine Dependence , smoke quantity/frequency , Pittsburg Sleep Quality Index ( PSQI ) , Profile Of Moods State ( POMS ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>To eligible , subject must : Be least 21 year age . Meet DSM 5 criterion alcohol use disorder least moderate severity ( AUDMS ) . Be seek treatment AUD desire reduction cessation drinking . Be able verbalize understanding consent form , able provide write informed consent , verbalize willingness complete study procedure , able understand write oral instruction English able complete questionnaire require protocol . Agree ( subject female child bear potential ) use least one follow method birth control , unless surgically sterile , partner surgically sterile postmenopausal : 1. oral contraceptive , 2. contraceptive sponge , 3. patch , 4. double barrier ( diaphragm/spermicidal condom/spermicidal ) , 5. intrauterine contraceptive system , 6. levonorgestrel implant , 7. medroxyprogesterone acetate contraceptive injection , 8. complete abstinence sexual intercourse , and/or 9. hormonal vaginal contraceptive ring . Be able take oral medication willing adhere medication regimen . Complete assessment require screening baseline . Have place live 2 week prior randomization risk s/he lose his/her housing next 2 month . Not anticipate significant problem transportation arrangement available time travel study site next 2 month . Not unresolved legal problem could jeopardize continuation completion study . And others . Contact site additional information</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>